NIHR Biomedical Research Centre: Oxford

Enabling translational research through partnership

NIHR 20th Anniversary NIHR website
NIHR Biomedical Research Centre: Oxford
  • Home
  • About
    • About us
    • Impact
    • Our next BRC
    • Steering Committee
    • Promoting equality, diversity and inclusion in research
    • Current Vacancies
    • Stay in Touch
    • Contact Us
  • Research
    • Research Overview
      • NIHR Clinical Research Facility
      • Ethics in the NIHR BRC: Oxford
      • Health Economics
      • Medical Statistics
    • Cancer
    • Cardiovascular Medicine
    • Digital Health from Hospital to Home
    • Gene and Cell Therapy
    • Genomic Medicine
    • Imaging
    • Inflammation across Tissues
    • Life-saving Vaccines
    • Metabolic Experimental Medicine
    • Modernising Medical Microbiology and Big Infection Diagnostics
      • Theme overview
      • Infections in Oxfordshire Database (IORD)
    • Musculoskeletal
    • Preventive Neurology
    • Respiratory Medicine
    • Surgical Innovation, Technology and Evaluation
    • Translational Data Science
  • Patient & Public Involvement
    • For patients and the public
    • For researchers
    • More information
  • Training
  • Industry & Partnerships
  • News
  • Events
  • Videos

News

Man treated in Oxford for blindness with gene therapy

27 October 2011 · Listed under Genomic Medicine, Surgical Innovation, Technology and Evaluation

Researchers in Oxford have treated a man with an advanced gene therapy technique to prevent him from losing his sight.

It is the first time that anyone has tried to correct a genetic defect in the light-sensing cells that line the back of the eye.

The president of the Academy of Medical Sciences said the widespread use of gene therapy of this treatment will be soon be possible.

The operation was carried out on 63-year-old Jonathan Wyatt by Professor Robert MacLaren and his team.

It is the first time that anyone has attempted to correct a gene defect in the light-sensing cells that line the back of the eye.

Mr Wyatt is the first of 12 patients undergoing this experimental technique over the next two years at the John Radcliffe Hospital in Oxford.

His doctor, Prof Robert MacLaren, believes that he’ll know for sure whether the degeneration in Mr Wyatt’s eye has stopped within two years. If that’s the case his vision will be saved indefinitely.

“If this works with then we would want to go in and treat patients at a much earlier stage in childhood, effectively where they still have normal vision and can do normal things to prevent them from losing sight.

Prof MacLaren believes that if this gene therapy works it could be used to treat a wide variety of eye disorders, including the most common form of blindness in the elderly, macular degeneration.

← Heart disease linked to a few rogue genes
First electronic retina implanted in the UK →

Other news

News Categories

News by Month

See all news
You are here: Home > Genomic Medicine > Man treated in Oxford for blindness with gene therapy

Subscribe to the BRC Oxford Newsletter

Keep informed about the work of the BRC Oxford by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

BRC Oxford on Social Media

  • Bluesky
  • Facebook
  • LinkedIn
  • YouTube
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2026 NIHR Biomedical Research Centre: Oxford